Phuongdung Nguyen, MD
Pulmonary Disease · Houston, TXNPI 1962486878
Payments from drug & device makers
Across 772 payments — averaging $122.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$70K
- Viatris Specialty LLC$7K
- Sanofi$4K
- GSK$3K
- Olympus Corporation Of The Americas$2K
- Actelion Pharmaceuticals US, Inc.$2K
- plus $8K from 30 others
What the payments were for
- Consulting fees$4,3585%
- Speaking & faculty fees$67,15771%
- Travel & lodging$3,4164%
- Food & beverage$19,32320%
- Education$3250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 200 | $70,116 |
| Viatris Specialty LLC | 15 | $6,608 |
| Sanofi | 63 | $4,224 |
| GSK | 141 | $2,694 |
| Olympus Corporation Of The Americas | 16 | $1,672 |
| Actelion Pharmaceuticals US, Inc. | 44 | $1,505 |
| Boehringer Ingelheim | 49 | $1,173 |
| Electromed, Inc. | 41 | $1,041 |
| Baxter Healthcare | 34 | $895 |
| Regeneron Healthcare Solutions, Inc. | 22 | $785 |
| Mylan Specialty L.p. | 30 | $621 |
| Bayer | 5 | $512 |
| United Therapeutics Corporation | 15 | $431 |
| Philips North America LLC | 19 | $325 |
| Insmed, Inc. | 15 | $312 |
| Amgen | 9 | $284 |
| Gilead | 3 | $143 |
| Mallinckrodt Hospital Products Inc. | 5 | $134 |
| AbbVie | 6 | $133 |
| Verona Pharma, Inc. | 6 | $120 |
| Coopersurgical, Inc. | 1 | $101 |
| ANI Pharmaceuticals, Inc. | 3 | $97 |
| Johnson & Johnson | 4 | $90 |
| Circassia Inc. | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
| Paratek Pharmaceuticals, Inc. | 2 | $62 |
| Advanced Respiratory, Inc | 2 | $54 |
| Genentech USA, Inc. | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Janssen Scientific Affairs, LLC | 1 | $44 |
| Merck | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Sandoz | 1 | $23 |
| Resmed Corp | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$64,161
- Yupelri$6,490
- DUPIXENT$2,590
- Single Use Guide Sheath Kit$1,303
- FASENRA$509
- Adempas$400
- BREZTRI$329
- TEZSPIRE$236
- SINGLE USE SUCTION VALVE (Sterile)$208
- TYVASO$123
- OFEV$122
- UPTRAVI$120
- OPSUMIT$120
- Vemlidy$106
- Laparoscopic Instruments$101
How this compares
$94,579 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $341,997 |
| UptraviSelexipag | 11 | $235,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 301 | $234,382 |
| OpsumitMacitentan | 11 | $129,775 |
| Dupixent PenDupilumab | 22 | $91,191 |
| Dupixent SyringeDupilumab | 22 | $80,145 |
| TezspireTezepelumab-Ekko | 12 | $52,764 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $49,579 |
| Spiriva RespimatTiotropium Bromide | 41 | $35,416 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $31,997 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $20,616 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $17,456 |
| EliquisApixaban | 20 | $17,182 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $9,911 |
| Sildenafil Citrate | 14 | $9,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,173 | $409,409121 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,505 | $365,13922 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,694 | $272,454367 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $70,116 | $112,254110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.